Involvement of protein kinase D in phosphorylation and increase of DNA binding of activator protein 2α to downregulate ATP-binding cassette transporter A1

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 12, 2008, Pages 2282-2287

  Iwamoto, Noriyuki ^a   Abe Dohmae, Sumiko ^a   Lu, Rui ^a   Yokoyama, Shinji ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

ABCA1; AP2 ; Atherosclerosis; Doxazosin; HDL; PKD

Indexed keywords

ABC TRANSPORTER A1; ACTIVATOR PROTEIN 2 ALPHA; HIGH DENSITY LIPOPROTEIN; POLYCYSTIN 1; PROTEIN KINASE D; PROTEIN SERINE KINASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR IIA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOGENESIS; CELL STRAIN HEK293; DNA BINDING; DOWN REGULATION; GENE EXPRESSION; GENE REPRESSION; LIPOPROTEIN BLOOD LEVEL; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; RAT;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BINDING SITES; CELL LINE; DNA; DOWN-REGULATION; HUMANS; LIPOPROTEINS, HDL; MICE; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN KINASE C; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; SERINE; TRANSCRIPTION FACTOR AP-2;

EID: 57549087200     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.108.174714     Document Type: Article

References (43)

1. Iwamoto N, Abe-Dohmae S, Ayaori M, Tanaka N, Kusuhara M, Ohsuzu F, Yokoyama S. ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha. Doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis independent of alpha1-adrenoceptor blockade. Circ Res. 2007;101:156-165.
2. Garcia MA, Campillos M, Marina A, Valdivieso F, Vazquez J. Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation. FEBS Lett. 1999;444:27-31.
3. Nishikawa K, Toker A, Johannes FJ, Songyang Z, Cantley LC. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J Biol Chem. 1997;272:952-960.
4. Williams T, Tjian R. Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins. Science. 1991;251: 1067-1071.
5. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol. 2005;6:246.1-246.8.
6. Ikeda K, Maegawa H, Ugi S, Tao Y, Nishio Y, Tsukada S, Maeda S, Kashiwagi A. Transcription factor activating enhancer-binding protein-2beta. A negative regulator of adiponectin gene expression. J Biol Chem. 2006;281:31245-31253.
7. Rozengurt E, Rey O, Waldron RT. Protein kinase D signaling. J Biol Chem. 2005;280:13205-13208.
8. Wang QJ. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci. 2006;27:317-323.
9. Valverde AM, Sinnett-Smith J, Van Lint J, Rozengurt E. Molecular cloning and characterization of protein kinase D: a target for diacylglycerol and phorbol esters with a distinctive catalytic domain. Proc Natl Acad Sci U S A. 1994;91:8572-8576.
10. Zugaza JL, Waldron RT, Sinnett-Smith J, Rozengurt E. Bombesin, vasopressin, endothelin, bradykinin, and platelet-derived growth factor rapidly activate protein kinase D through a protein kinase C-dependent signal transduction pathway. J Biol Chem. 1997;272:23952-23960.
11. Tan M, Xu X, Ohba M, Ogawa W, Cui MZ. Thrombin rapidly induces protein kinase D phosphorylation, and protein kinase C delta mediates the activation. J Biol Chem. 2003;278:2824-2828.
12. Yuan J, Slice LW, Gu J, Rozengurt E. Cooperation of Gq, Gi, and G12/13 in protein kinase D activation and phosphorylation induced by lysophosphatidic acid. J Biol Chem. 2003;278:4882-4891.
13. Zhukova E, Sinnett-Smith J, Rozengurt E. Protein kinase D potentiates DNA synthesis and cell proliferation induced by bombesin, vasopressin, or phorbol esters in Swiss 3T3 cells. J Biol Chem. 2001;276: 40298-40305.
14. Wang Y, Waldron RT, Dhaka A, Patel A, Riley MM, Rozengurt E, Colicelli J. The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol. 2002;22:916-926.
15. Pfisterer P, Ehlermann J, Hegen M, Schorle H. A subtractive gene expression screen suggests a role of transcription factor AP-2 alpha in control of proliferation and differentiation. J Biol Chem. 2002;277: 6637-6644.
16. Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, Glazer PM, Hurst HC, Haffty BG, Williams T. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res. 1998;58:5466-5472.
17. Hoei-Hansen CE, Nielsen JE, Almstrup K, Sonne SB, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E. Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res. 2004;10: 8521-8530.
18. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene. 1996;13:1701-1707.
19. Hu W, Abe-Dohmae S. Tsujita M, Iwamoto N, Ogikubo O, Otsuka T, Kumon Y, Yokoyama S. Biogenesis of HDL by SAA is dependent on ABCA1 in the liver in vivo. J Lipid Res. 2008;49:386-393.
20. Yokoyama S, Tajima S, Yamamoto A. The process of dissolving apolipoprotein A-I in an aqueous buffer. J Biochem (Tokyo). 1982;91: 1267-1272.
21. Buettner R, Kannan P, Imhof A, Bauer R, Yim SO, Glockshuber R, Van Dyke MW, Tainsky MA. An alternatively spliced mRNA from the AP-2 gene encodes a negative regulator of transcriptional activation by AP-2. Mol Cell Biol. 1993;13:4174-4185.
22. Williams T, Admon A, Luscher B, Tjian R. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev. 1988;2:1557-1569.
23. Zugaza JL, Sinnett-Smith J, Van Lint J, Rozengurt E. Protein kinase D (PKD) activation in intact cells through a protein kinase C-dependent signal transducation pathway. EMBO J. 1996;15:6220-6230.
24. Rykx A, De Kimpe L, Mikhalap S, Vantus T, Seufferlein T, Vandenheede JR, Van Lint J. Protein kinase D: a family affair. FEBS Lett. 2003;546:81-86.
25. Jacamo R, Sinnett-Smith J, Rey O, Waldron RT, Rozengurt E. Sequential PKC-dependent and PKC-independent protein kinase D catalytic activation via Gq-coupled receptors: Differential regulation of activation loop Ser744 and Ser748 phosphorylation. J Biol Chem. 2008;283:12877-12887.
26. Yokoyama S. Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol. 2006;26:20-27.
27. Huang Y, Domann FE. Redox modulation of AP-2 DNA binding activity in vitro. Biochem Biophys Res Commun. 1998;249:307-312.
28. Eloranta JJ, Hurst HC. Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J Biol Chem. 2002;277:30798-30804.
29. Johannes FJ, Prestle J, Eis S, Oberhagemann P, Pfizenmaier K. PKCu is a novel, atypical member of the protein kinase C family. J Biol Chem. 1994;269:6140-6148.
30. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298: 1912-1934.
31. Storz P, Toker A. Protein kinase D mediates a stress-induced NF-kappaB activation and survival pathway. EMBO J. 2003;22: 109-120.
32. Gschwendt M, Dieterich S, Rennecke J, Kittstein W, Mueller HJ, Johannes FJ. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996; 392:77-80.
33. Kim MS, Wang F, Puthanveetil P, Kewalramani G, Hosseini-Beheshti E, Ng N, Wang Y, Kumar U, Innis S, Proud CG, Abraham A, Rodrigues B. Protein kinase D is a key regulator of cardiomyocyte lipoprotein lipase secretion after diabetes. Circ Res. 2008;103:252-256.
34. Sinnett-Smith J, Zhukova E, Hsieh N, Jiang X, Rozengurt E. Protein kinase D potentiates DNA synthesis induced by Gq-coupled receptors by increasing the duration of ERK signaling in Swiss 3T3 cells. J Biol Chem. 2004;279:16883-16893.
35. Fernando MA, Heaney AP. Alphal-adrenergic receptor antagonists: novel therapy for pituitary adenomas. Mol Endocrinol. 2005;19: 3085-3096.
36. Gonzalez-Juanatey JR, Iglesias MJ, Alcaide C, Pineiro R, Lago F. Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of alpha1-adrenergic blockade. Circulation. 2003;107:127-131.
37. Benning CM, Kyprianou N. Quinazoline-derived alphal-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor- independent action. Cancer Res. 2002;62:597-602.
38. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res. 2001;14:78-85.
39. Roth M, Emmons LR, Perruchoud A, Block LH. Expressions of the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase genes are stimulated by recombinant platelet-derived growth factor isomers. Proc Natl Acad Sci U S A. 1991;88:1888-1892.
40. Witte LD, Cornicelli JA. Platelet-derived growth factor stimulates low density lipoprotein receptor activity in cultured human fibroblasts. Proc Natl Acad Sci U S A. 1980;77:5962-5966.
41. Nagao S, Murao K, Imachi H, Cao WM, Yu X, Li J, Matsumoto K, Nishiuchi T, Ahmed RA, Wong NC, Ueda K, Ishida T. Platelet derived growth factor regulates ABCA1 expression in vascular smooth muscle cells. FEBS Lett. 2006;580:4371-4376.
42. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest. 2005;115:959-968.
43. Fielding CJ, Bist A, Fielding PE. Intracellular cholesterol transport in synchronized human skin fibroblasts. Biochemistry. 1999;38:2506-2513.